A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma

NCT01766583 | Completed Phase 1 DMC

• 1 other identifier: CLEAR
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 6

Brief Summary

This is an open label, 3 + 3 dose escalation study, to determine the MTD, safety, efficacy and PK profiles for subjects with relapsed/refractory B-cell malignancies when using CC-292 and lenalidomide combination therapy. Subjects will be followed for disease progression and collection of second primary malignancy (SPM) events. This dose escalation will be followed by an exploratory expansion phase in 3 cohorts of 12 patients each.

Conditions

Relapsed/Refractory B-cell Lymphoma

Keywords

Open label, 3 + 3 dose escalation study followed by an expansion phase.

Outcome Measures

Primary Outcomes (1)

• Determination of the recommended dose of CC-292 and lenalidomide in patients with relapsed/refractory B-cell lymphoma

  The optimal CC-292 and lenalidomide combination will be determined based on the maximum tolerated dose (MTD), the dose limiting toxicities (DLT) and/or the analysis of adverse events, serious adverse events and toxicities observed during the study

  28 days

Secondary Outcomes (8)

• preliminary efficacy signals of the CC-292 + Lenalidomide combination

  6 months

• Observed maximum plasma concentration

  0, 0.5, 1, 2, 4, 6, 8 hours post dose

• time to reach maximum observed plasma concentration (Tmax)

  0, 0.5, 1, 2, 4, 6, 8 hours post dose

• Terminal phase rate constant (λz)

  0, 0.5, 1, 2, 4, 6, 8 hours post dose

• plasma decay half-life (t1/2)

  0, 0.5, 1, 2, 4, 6, 8 hours post dose

Study Arms (1)

CC-292 + lenalidomide

EXPERIMENTAL

Combination of CC-292 + lenalidomide

Drug: CC-292 + lenalidomide

Interventions

CC-292 + lenalidomide DRUG

CC-292 + lenalidomide

CC-292 + lenalidomide

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histology:
• Patients with any type of B-cell Lymphoma except CLL, SLL and Waldenström disease will be eligible during the dose escalation phase
• During the expansion phases, patients with DLBCL for cohort A, mantle cell lymphoma for cohort B and any other type of B-cell lymphoma except CLL, SLL and Waldenström disease for cohort C.
• Other criteria:
• Signed inform consent
• Patients should be relapsed or refractory NHL after ≥1 prior Rituximab-containing regimen for which no other type of therapy is of higher priority
• Aged 18 years or more.
• ECOG performance status 0-2.
• Measurable disease defined by at least one single node or tumor lesion \> 1.5 cm.
• Life expectancy of ≥ 90 days (3 months).
• Patients must be eligible and willing to undergo excisional biopsies of tumor sites with a lymph node of minimum 1 cm at baseline and after 21 days of treatment
• Females of childbearing potential (FCBP)† must have two negative serum or urine pregnancy tests with a sensitivity of at least 25 mIU/mL before starting lenalidomide - the first test must be performed within 10-14 days before starting lenalidomide treatment and the second test must be performed within 24 hours before starting lenalidomide
• FCBP must either commit to continued abstinence from heterosexual intercourse or begin two methods of birth control, at least 4 weeks before she starts taking lenalidomide. FCBP must also agree to monthly pregnancy testing and must be counseled at a minimum of every 4 weeks about pregnancy precautions and risks of fetal exposure.
• Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential. Men must also be counseled at a minimum of every 4 weeks about pregnancy precautions and risks of fetal exposure.

You may not qualify if:

• Previous treatment with lenalidomide or a BTK inhibitor. Central nervous system or meningeal involvement. Contraindication to any drug contained in this regimen Concomitant use of medicines known to cause QT prolongation or torsades de pointes HIV disease, active hepatitis B or C. Any serious active disease or co-morbid medical condition (according to investigator's decision);
• Any of the following laboratory abnormalities :
• Absolute neutrophil count (ANC) \< 1,500 cells/mm3 (1.5 x 109/L).
• Platelet count \< 80,000/mm3 (80 x 109/L)
• Serum SGOT/AST or SGPT/ALT \>3.0 x upper limit of normal (ULN).
• Serum total bilirubin \> 1.5 ULN except in case of hemolytic anemia and Gilbert's syndrome.
• Calculated creatinine clearance (Cockcroft-Gault formula or MDRD) of \< 50 mL /min Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast or Incidental histological finding of prostate cancer \[TNM stage of T1a or T1b\]) unless the subject has been free of the disease for ≥ 5 years Any serious medical condition, laboratory abnormality, or psychiatric illnessthat would prevent the subject from signing the informed consent form.
• Pregnant or lactating females. Prior ≥ Grade 3 allergic reaction/hypersensitivity to thalidomide and/or pomalidomide.
• Prior ≥ Grade 3 rash or any desquamating (blistering) rash while taking thalidomide and/or pomalidomide.
• Subjects with ≥ Grade 2 neuropathy. Use of any standard or experimental anti-cancer drug therapy within 28 days of the initiation (Day 1) of study drug therapy.
• Chronic use of proton pump inhibitors, H2 antagonists or antacids or their use in the last 7 days prior to the first CC-292 dose. Patients with chronic gastroesophageal reflux disease, dyspepsia, and peptic ulcer disease, should be carefully evaluated for their suitability for this treatment prior to enrollment in this study. These medications should be avoided throughout the study.

Sponsors & Collaborators

• The Lymphoma Academic Research Organisation: lead
• Celgene Corporation: collaborator

Study Sites (6)

Hopital henri mondor

Créteil, 94010, France

Location

CHU de Lille

Lille, 59037, France

Location

Institut Paoli Calmette

Marseille, 13273, France

Location

CHU de Nantes

Nantes, 44093, France

Location

CHU Lyon Sud

Pierre-Bénite, 69495, France

Location

CHU de Toulouse

Toulouse, 31059, France

Location

Related Links

• LYSA (the Lymphoma Study Association)

MeSH Terms

Conditions

Lymphoma, B-Cell

Interventions

spebrutinib; Lenalidomide

Condition Hierarchy (Ancestors)

Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Phthalimides; Phthalic Acids; Acids, Carbocyclic; Carboxylic Acids; Organic Chemicals; Piperidones; Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Isoindoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Officials

• Gilles Salles, PhD

  CHU Lyon - Sud - LYSA

  STUDY CHAIR

• Loïc YSEBAERT, MD

  CHU de Toulouse LYSA

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 29, 2012
• First Posted: January 11, 2013
• Study Start: February 1, 2013
• Primary Completion: November 1, 2014
• Study Completion: January 1, 2018
• Last Updated: March 7, 2018

Record last verified: 2018-03

Locations

FR (6)